Signal transduction in urothelial cancer: How exactly do we know the targets for targeted therapy?;Signaltransduktion im Urothelkarzinom: Wie genau kennen wir die Ziele für eine zielgerichtete Therapie?

Urologe - Ausgabe A

Volumn 49, Issue 11, 2010, Pages 1401-1405

  Niegisch, G ^a   Koch, A ^a   Knievel, J ^a   Schulz, W A ^a   Albers, P ^a  

^a Department of Orthopedic Surgery   (Germany)

Author keywords

Cancer pathways; Cell cycle control; Receptor pathways; Targeted therapy; Urothelial cancer

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B;

CANCER GENETICS; CELL CYCLE; EPIGENETICS; GENE MUTATION; HUMAN; PAPILLOMA; REVIEW; SIGNAL TRANSDUCTION; UROGENITAL TRACT CANCER;

ANIMALS; HUMANS; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 78650191856     PISSN: 03402592     EISSN: 14330563     Source Type: Journal    
DOI: 10.1007/s00120-010-2448-8     Document Type: Review

References (25)

1. Bardelli A, Siena S (2010) Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 28:1254-1261
2. Bartkova J, Horejsi Z, Koed K et al (2005) DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434:864-870
3. Billerey C, Chopin D, Aubriot-Lorton MH et al (2001) Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 158:1955-1959
4. Cappellen D, De Oliveira C, Ricol D et al (1999) Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 23:18-20
5. Chatterjee SJ, Datar R, Youssefzadeh D et al (2004) Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 22:1007-1013
6. Cohen DJ, Hochster HS (2007) Update on clinical data with regimens inhibiting angiogenesis and epidermal growth factor receptor for patients with newly diagnosed metastatic colorectal cancer. Clin Colorectal Cancer 7 (Suppl 1):21-27
7. Cunningham D, Atkin W, Lenz HJ et al (2010) Colorectal cancer. Lancet 375:1030-1047
8. Florl AR, Schulz WA (2008) Chromosomal instability in bladder cancer. Arch Toxicol 82:173-182
9. Frolov MV, Dyson NJ (2004) Molecular mechanisms of E2F-dependent activation and pRB-mediated repression. J Cell Sci 117:2173-2181
10. Gu W, Roeder RG (1997) Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90:595-606
11. Hoshino R, Chatani Y, Yamori T et al (1999) Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18:813-822
12. Jebar AH, Hurst CD, Tomlinson DC et al (2005) FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 24:5218-5225
13. Knowles MA (2008) Molecular pathogenesis of bladder cancer. Int J Clin Oncol 13:287-297
14. Lindgren D, Frigyesi A, Gudjonsson S et al (2010) Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res 70:3463-3472
15. Lopez-Knowles E, Hernandez S, Malats N et al (2006) PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res 66:7401-7404
16. Merseburger AS, Waalkes S, Kuczyk MA (2009) Current state of systemic therapy of metastatic renal cell carcinoma. Urologe A 48:983-989
17. Qu W, Kang YD, Zhou MS et al (2009) Experimental study on inhibitory effects of histone deacetylase inhibitor MS-275 and TSA on bladder cancer cells. Urol Oncol, doi:10.1016/j.urolonc.2008.11.018
18. Ringhoffer M, Rinnab L, Kufer R et al (2009) Systemic therapy of metastatic renal cell carcinoma: from many options to the therapeutic strategy. Urologe A 48:1308-1317
19. Schulz W (2007) Molecular biology of human cancers. Springer, Dordrecht
20. Schulz WA (2006) Understanding urothelial carcinoma through cancer pathways. Int J Cancer 119:1513-1518
21. Shi T P, Xu H, Wei JF et al (2008) Association of low expression of notch-1 and jagged-1 in human papillary bladder cancer and shorter survival. J Urol 180:361-366
22. Siddiqui H, Solomon DA, Gunawardena RW et al (2003) Histone deacetylation of RB-responsive promoters: requisite for specific gene repression but dispensable for cell cycle inhibition. Mol Cell Biol 23:7719-7731
23. Swiatkowski S, Seifert HH, Steinhoff C et al (2003) Activities of MAP-kinase pathways in normal uroepithelial cells and urothelial carcinoma cell lines. Exp Cell Res 282:48-57
24. Tomlinson DC, Baldo O, Harnden P et al (2007) FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol 213:91-98
25. Van Rhijn BW, Lurkin I, Radvanyi F et al (2001) The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 61:1265-1268